Patients with haemophilia A with inhibitors in China: a national real‐world analysis and follow‐up
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Haematology"
DOI: 10.1111/bjh.17322
Abstract: The development of alloantibodies (inhibitors) against coagulation factor VIII (FVIII) is the most serious complication of FVIII replacement therapy in patients with haemophilia A (HA). We carried out a nationwide study focussing on patients with… read more here.
Keywords: real world; patients haemophilia; haemophilia inhibitors; china national ... See more keywords
Perioperative haemostasis in children with haemophilia and inhibitors during central venous catheter surgery: The Karolinska model
Sign Up to like & getrecommendations! Published in 2018 at "Haemophilia"
DOI: 10.1111/hae.13594
Abstract: national tender process with higher prices per unit for standard FVIII and FIX concentrates, the absence of difference in price per unit for standard FVIII and EHLFVIII concentrates, the only recent introduction of a network… read more here.
Keywords: children haemophilia; inhibitors central; haemophilia inhibitors; haemostasis children ... See more keywords
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "Haemophilia"
DOI: 10.1111/hae.14418
Abstract: Surgical procedures in persons with haemophilia A or B with inhibitors (PwHABI) require the use of bypassing agents (BPA) and carry a high risk of complications. Historically, only two BPAs have been available; these are… read more here.
Keywords: clinical trial; trial evaluate; haemophilia inhibitors; persept phase ... See more keywords
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14563
Abstract: Eptacog beta is a new recombinant activated human factor VII bypassing agent approved in the United States for the treatment and control of bleeding in patients with haemophilia A or B with inhibitors 12 years… read more here.
Keywords: haemophilia inhibitors; eptacog beta; control bleeding; treatment control ... See more keywords
Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow‐up from the UK Haemophilia Centre Doctors’ Organisation (UKHCDO)
Sign Up to like & getrecommendations! Published in 2023 at "Haemophilia"
DOI: 10.1111/hae.14762
Abstract: The UK National Haemophilia Database (NHD) collects data from all UK persons with haemophilia A with inhibitors (PwHA‐I). It is well‐placed to investigate patient selection, clinical outcomes, drug safety and other issues not addressed in… read more here.
Keywords: prophylaxis haemophilia; haemophilia inhibitors; inhibitors three; emicizumab prophylaxis ... See more keywords
Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors.
Sign Up to like & getrecommendations! Published in 2017 at "Thrombosis and haemostasis"
DOI: 10.1160/th17-05-0365
Abstract: Patients with haemophilia and inhibitors to factors VIII or IX require bypassing therapy. The primary safety concern of bypassing agents is thromboembolism; however, the incidence of thromboembolic adverse events (TAEs) in haemophilia patients with inhibitors… read more here.
Keywords: use bypassing; patients haemophilia; haemophilia inhibitors; events per ... See more keywords